Targeted Intensification With ZBEAM & Autologous Stem Cell Transplantation

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined with high-dose BEAM followed by ASCT after first line treatment in patients aged from 18 to 65 years with poor prognosis CD 20 Diffuse Large B-Cell lymphoma

See also
Status	Clinical Trial	Phase
Completed	`NCT00532259` - CT-011 MAb in DLBCL Patients Following ASCT	Phase 2
Terminated	`NCT00322218` - Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.	Phase 3
Completed	`NCT00436280` - Chemotherapy for Participants With Lymphoma	Phase 2

NCT number	NCT00689169
Study type	Interventional
Source	Lymphoma Study Association
Contact
Status	Completed
Phase	Phase 2
Start date	August 2007
Completion date	January 2014

Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma — ZBEAM2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms